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between the two groups was used Chi Square Test. To evaluate
differences in EQ VAS was used both Paired sample T test and
a regression analysis using bootstrap estimated of standard error.
RESULTS: No statistically signiﬁcant differences were reported
in all dimensions between the two groups: mobility (P = 1.000),
self care (P = 0.064), usual activities (P = 0.213), pain/discom-
fort (P = 0.213) and anxiety/depression (P = 0.512). The ﬁgures
obtained using VAS to assess the global health status was: 72.8
(SD, ± 19.7) in patients treated with VKA and 73.9 (SD, ± 16.0)
in matched controls; this difference was not statistically signiﬁ-
cant (p = 0.708 Paired sample T); also bootstrap conﬁdent 
intervals indicated that there was no statistically signiﬁcant 
differences between the two groups. CONCLUSIONS: Even if it
is conceivable that different settings would give different results,
our study show that in patients on oral anticoagulant treatment
the overall perception of health status was not signiﬁcantly dif-
ferent from that of matched controls.
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OBJECTIVE: Wide use of disease-oriented quality of life (QoL)
measures, that are not preference based, and thus lack legitimacy
for direct use in economic evaluations, has prompted a need for
modeling to derive utilities. The QoL Assessment of Growth
Hormone Deﬁciency in Adults questionnaire (QoL-AGHDA) is
a disease-oriented measure used to assess impairment in QoL in
adults with growth hormone deﬁciency. The present study aims
to provide a model for deriving utilities directly from the QoL-
AGHDA. METHODS: The EQ-5D and the QoL-AGHDA were
mailed to a random sample (n = 2990) of the Swedish popula-
tion (response rate, 65%). The Jack knife method was used to
obtain cross-validated parameters of QoL-AGHDA-based utili-
ties. Using the EQ-5Dindex (derived from European values) as the
dependent variable, and age, gender and QoL-AGHDA score as
independent variables in repeated regression analyses, each time
omitting one tenth of the sample (the Jack-knife method) esti-
mates for the coefﬁcients for transformation of the QoL-
AGHDA into a single score (range, 0–1) were achieved. These
transformed QoL-AGHDA scores correspond to the QoL-
AGHDA-based utility. RESULTS: The transformation algorithm
was: U (QoL-AGHDA-based utilities) = [102.2 - 1.80*QoL-
AGHDA score - 0.227 * age - 1.21*Gender (men = 0; women
= 1)]/100. The mean of the weighted estimate for the total pop-
ulation (n = 1752) was 0.83 (SD, 0.09). The estimate for men (n
= 861; mean, 0.84; SD, 0.09) was higher (p < 0.001) than for
women (n = 891; mean, 0.82; SD, 0.09). CONCLUSION: The
present model could be used to derive utilities directly from the
QoL-AGHDA; however, it should be highlighted that the coefﬁ-
cients presented here come from the homogeneous Swedish pop-
ulation and thus application to other populations should be
carefully considered.
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Although the beneﬁcial effect of growth hormone replacement
on QoL in adults with GHD is well recognized, the long-term
effect of this therapy on QoL remains uncertain. OBJECTIVES:
To determine the effect of long term GH replacement on QoL in
patients compared with country-speciﬁc normative data for the
general population (GP). METHODS: QoL was measured using
Quality of Life Assessment for Growth Hormone Deﬁciency in
Adults (QoL-AGHDA) in patients and GP in Sweden and
England & Wales (E&W). QoL-AGHDA is a 25-item question-
naire that elicits yes/no responses that are used to compute a
summary score. GP data were obtained from 1682 randomly
selected individuals from Sweden and 892 from E&W. These
data were compared with KIMS (Pﬁzer International Metabolic
Database) data for 121 patients from Sweden and 77 from E&W
with 5 years of complete follow-up. Age-range was 20–79 years.
Linear regression methods were used to estimate age- and
gender-adjusted differences between patients and the GP at one-
year intervals. The signiﬁcance level was set at 5%. RESULTS:
The (adjusted to age 50) mean QoL-AGHDA score at baseline
were 8.21 and 15.2 (SEM 0.44 and 0.68) for the Swedish and
E&W patients, respectively. For the GP samples the corre-
sponding mean scores were 3.80 and 6.6 (SEM 0.12 and 0.20).
The mean difference between patient scores at baseline and GP
scores were -4.4 for Sweden and -8.6 for E&W (p < 0.0001).
However, these differences reduced markedly over the ﬁrst year
of treatment and were subsequently maintained at statistically
non-signiﬁcant differences compared to the general populations.
CONCLUSIONS: This study shows that adults with GHD who
receive long-term GH replacement beneﬁt most with respect to
QoL during the ﬁrst 12 months of therapy and that this improve-
ment was maintained at levels close to normalization in QoL
over 5 years of follow up.
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OBJECTIVES: To evaluate the impact of acromegaly on health-
related quality of life (HRQOL) in European patients treated
with Sandostatin® LAR®. The secondary objectives were to
investigate the correlation between HRQOL and subpopulations
based on exploratory variables [sociodemographic and disease-
